105 related articles for article (PubMed ID: 33129609)
21. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults.
Campbell JD; Clement KH; Wasserman SS; Donegan S; Chrisley L; Kotloff KL
Hum Vaccin; 2007; 3(5):205-11. PubMed ID: 17881903
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
[TBL] [Abstract][Full Text] [Related]
23. Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: a phase 4, open-label, parallel-group, randomised non-inferiority study.
Skoura N; Wang-Jairaj J; Della Pasqua O; Chandrasekaran V; Billiard J; Yeakey A; Smith W; Steel H; Tan LK
Lancet Infect Dis; 2020 Aug; 20(8):983-991. PubMed ID: 32333847
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents.
King JC; Gao Y; Quinn CP; Dreier TM; Vianney C; Espeland EM
Vaccine; 2015 May; 33(21):2470-6. PubMed ID: 25850022
[TBL] [Abstract][Full Text] [Related]
26. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
Zeng M; Xu Q; Pichichero ME
Vaccine; 2007 May; 25(18):3588-94. PubMed ID: 17293013
[TBL] [Abstract][Full Text] [Related]
27. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019.
Bower WA; Schiffer J; Atmar RL; Keitel WA; Friedlander AM; Liu L; Yu Y; Stephens DS; Quinn CP; Hendricks K;
MMWR Recomm Rep; 2019 Dec; 68(4):1-14. PubMed ID: 31834290
[TBL] [Abstract][Full Text] [Related]
28. Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959].
Zink TK
Vaccine; 2007 Apr; 25(15):2766-7. PubMed ID: 17224206
[TBL] [Abstract][Full Text] [Related]
29. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
[TBL] [Abstract][Full Text] [Related]
30. Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated.
Dumas EK; Garman L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Choudhari S; Picking WD; James JA; Farris AD
Vaccine; 2017 Jun; 35(26):3416-3422. PubMed ID: 28504191
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.
Kang CK; Kim NH; Kim CJ; Rhie GE; Jo SK; Ahn M; Kang J; Choe PG; Park WB; Kim NJ; Oh MD
Vaccine; 2019 Jun; 37(29):3820-3824. PubMed ID: 31151800
[TBL] [Abstract][Full Text] [Related]
32. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
[TBL] [Abstract][Full Text] [Related]
33. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
34. Bridging non-human primate correlates of protection to reassess the Anthrax Vaccine Adsorbed booster schedule in humans.
Schiffer JM; Chen L; Dalton S; Niemuth NA; Sabourin CL; Quinn CP
Vaccine; 2015 Jul; 33(31):3709-16. PubMed ID: 26072016
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
37. Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients.
Dumas EK; Gross T; Larabee J; Pate L; Cuthbertson H; Charlton S; Hallis B; Engler RJM; Collins LC; Spooner CE; Chen H; Ballard J; James JA; Farris AD
Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877928
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
39. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
40. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.
Quinn CP; Sabourin CL; Schiffer JM; Niemuth NA; Semenova VA; Li H; Rudge TL; Brys AM; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Parker SD; Babcock J; Keitel W; Poland GA; Keyserling HL; El Sahly H; Jacobson RM; Marano N; Plikaytis BD; Wright JG
Clin Vaccine Immunol; 2016 Apr; 23(4):326-38. PubMed ID: 26865594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
